Thrombosis Journal最新文献

{"title":"Hypofibrinogenemia caused by a heterozygous variant in the FGA gene: a case report.","authors":"Haoyu Wei, Xinhong Yang","doi":"10.1186/s12959-026-00891-4","DOIUrl":"10.1186/s12959-026-00891-4","url":null,"abstract":"<p><strong>Background: </strong>Hereditary Fibrinogen Disorders (HFDs) are conventionally classified as quantitative (type I) or qualitative (type II) deficiencies based on the plasma concentration. Quantitative deficiencies include afibrinogenemia/severe hypofibrinogenemia and hypofibrinogenemia, while qualitative deficiencies comprise dysfibrinogenemia and hypodysfibrinogenemia.</p><p><strong>Objective: </strong>To identify the molecular pathogenesis of hypofibrinogenemia in a pregnant patient and her family, and explore the clinical characteristics and peripartum management strategy of this disease.</p><p><strong>Methods: </strong>We described the clinical data and genetic findings of a 28-year-old pregnant woman and her mother with hypofibrinogenemia. Sanger sequencing was used to verify the heterozygous variant c.1517del (exon 5) of the FGA gene (NM_021871.4). Relevant published literatures were analyzed to summarize the research progress and clinical implications of this variant.</p><p><strong>Results: </strong>We identified a novel pathogenic FGA c.1517del variant in a Chinese family with hereditary hypofibrinogenemia. The proband presented with decreased fibrinogen activity (1.6 g/L) and antigen level (1.7 g/L), with an activity/antigen ratio of 0.94; her mother showed similar laboratory abnormalities. The patient received 1.5 g intravenous fibrinogen before neuraxial anesthesia-assisted lower-segment cesarean section. A 3.53 kg female neonate was delivered smoothly without obvious intraoperative hemorrhage.</p><p><strong>Conclusion: </strong>The diagnosis of HFDs relies on combined detection of fibrinogen function, antigen level and genetic analysis. Genetic screening facilitates clinical diagnosis and genetic counseling. For pregnant patients with hypofibrinogenemia in late gestation, preoperative fibrinogen supplementation can effectively correct coagulation defects and ensure safe delivery.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13536721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148296455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology.","authors":"Angela Misic, Ghadi Ghanem, Saeed Sadeghi, Matthew Carroll","doi":"10.1186/s12959-026-00887-0","DOIUrl":"10.1186/s12959-026-00887-0","url":null,"abstract":"<p><strong>Background: </strong>Hydroxyurea (HU) is a first-line oral cytoreductive agent for selected patients with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), due to its efficacy and tolerability. Although cutaneous ulceration is a recognized complication of long-term HU exposure, HU-associated digital gangrene is rare, and upper-extremity involvement in PV has not previously been reported.</p><p><strong>Case presentation: </strong>We describe the first case of HU-associated digital gangrene in a patient with PV. A 72-year-old man with well-controlled Janus kinase 2 (JAK2)-positive PV, treated with HU for more than a decade, developed painless dry gangrene of the right index and middle fingers. Vascular imaging showed no significant arterial occlusion or embolic source. Hematologic parameters remained within target ranges, and the workup for autoimmune disease, infection, and hypercoagulability was unremarkable. HU was discontinued, and the ischemia stabilized without surgical intervention. With no alternative etiology identified, delayed HU-associated vasculopathy was suspected.</p><p><strong>Conclusions: </strong>Our literature review identified three previously reported cases of HU-associated digital gangrene, though limited to the lower extremities - two in chronic myeloid leukemia (CML) and one in sickle cell disease (SCD). In each case, gangrene developed after prolonged HU exposure, alternative etiologies were not substantiated, and stabilization or clinical improvement followed HU withdrawal. The present case aligns with this pattern while extending the reported phenotype to well-controlled PV and upper-extremity digits. Given the small number of reported cases, the pathophysiology remains incompletely defined and is largely extrapolated from studies of more frequently described HU-associated ulceration, histopathologic reports of HU-related tissue injury, and in vitro studies of HU effects on endothelial and circulating cells. Plausible mechanisms include cumulative endothelial injury, localized thrombo-occlusive microvascular dysfunction, impaired vascular and cutaneous repair, and interaction with PV-related microvascular susceptibility. Clinicians should include HU-associated vasculopathy in the differential diagnosis of otherwise unexplained digital ischemia, as prompt drug cessation may limit progression and improve digit salvage.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148284577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Management of patients with protein s deficiency: focus on clinical course and direct oral anticoagulants.","authors":"Nicola Altamura, Filippo Giorgio Di Girolamo, Paola Pradella, Martina Cavalet, Federica Pellicori, Pierandrea Vinci, Emiliano Panizon, Giovanni Cominotto, Michele Zaccari, Irma Galasso, Paola La Rocca, Kaja Teraž, Massimo La Raja, Nicola Fiotti, Gianni Biolo","doi":"10.1186/s12959-026-00884-3","DOIUrl":"10.1186/s12959-026-00884-3","url":null,"abstract":"","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"24 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13270608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relapsing polychondritis in a patient with suspected antiphospholipid syndrome presenting with inferior vena cava thrombosis: Palestinian case report.","authors":"Elias Amarneh, Alfarouq Alboom, Ghayda' Sharif, Ayah Abulehia, Nour AlMaqadma","doi":"10.1186/s12959-026-00878-1","DOIUrl":"10.1186/s12959-026-00878-1","url":null,"abstract":"<p><strong>Background: </strong>Antiphospholipid syndrome (APS) is an autoimmune thrombophilia characterized by arterial and venous thrombosis that commonly affects the deep veins of the lower extremities and cerebral vasculature. Inferior vena cava (IVC) thrombosis is an extremely rare manifestation of APS and is often associated with hypercoagulable states. Relapsing polychondritis (RPC) is an autoimmune disorder affecting cartilaginous structures, sometimes occurring alongside APS. However, the coexistence of primary suspected APS and RPC has rarely been reported.</p><p><strong>Case presentation: </strong>A 33-year-old previously healthy male who presented with fever, acute right-sided flank pain, and systemic symptoms. Initial evaluation revealed urolithiasis, but persistent pain and elevated inflammatory markers prompted further imaging, which revealed IVC thrombosis.</p><p><strong>Conclusion: </strong>This case highlights the importance of recognizing suspected APS in patients presenting with unprovoked IVC thrombosis and highlights RPC as a potential autoimmune comorbidity. Although APS is a well-established prothrombotic disorder, its coexistence with RPC remains uncommon and poorly understood. The presence of antiphospholipid antibodies may contribute to the vascular inflammation observed in RPCs, suggesting a possible pathogenic link between these two conditions. Further studies are needed to explore the relationship between APS and RPC and refine diagnostic and therapeutic approaches.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13501687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148253420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative management in a patient with congenital factor VII deficiency following mechanical valve replacement: a case report.","authors":"Xiaokang Luo, Xue Yang, Tucheng Sun, Xinjian Yan","doi":"10.1186/s12959-026-00886-1","DOIUrl":"10.1186/s12959-026-00886-1","url":null,"abstract":"<p><strong>Background: </strong>Congenital factor VII deficiency (CFVIID) is a rare hemorrhagic disorder which elevates perioperative bleeding risks. Mechanical prosthesis mandates lifelong anticoagulation, while international normalized ratio (INR) of CFVIID deviates significantly from the normal range which could not accurately reflect the real anticoagulation. Perioperative management for CFVIID patients undergoing mechanical valve replacement are highly challenging, with no clinical guidelines currently available.</p><p><strong>Case presentation: </strong>We reported a 59-year-old CFVIID patient undergoing mechanical valve replacement. Perioperative recombinant activated factor VII (rFVIIa) replacement secured hemostasis. After postoperative cerebral thrombosis, anticoagulation of warfarin was initiated and guided by factor Ⅱ/Ⅹ activity (30-45%) rather than INR. No bleeding or recurrent thrombosis was observed.</p><p><strong>Conclusions: </strong>Perioperative rFVIIa replacement guarantees hemostatic safety for cardiac surgery. Lifelong warfarin anticoagulation is essential for CFVIID patient with mechanical prosthesis. Monitoring factor Ⅱ/Ⅹ activity instead of INR can balance bleeding and thrombosis risks for such cases.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13501598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148253342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging strategies in venous thromboembolism: a narrative review of pharmacological innovations.","authors":"Juan Ye, Kun Huang","doi":"10.1186/s12959-026-00882-5","DOIUrl":"10.1186/s12959-026-00882-5","url":null,"abstract":"<p><p>Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major cause of preventable morbidity and mortality and is increasingly recognized as a chronic vascular disease. Although direct oral anticoagulants (DOACs) have simplified management, clinically important limitations remain. Major bleeding still occurs in roughly 2-4% of treated patients per year and clinically relevant nonmajor bleeding in 10-12%, while post-thrombotic syndrome (PTS) after proximal DVT and persistent functional limitation after PE continue to impair quality of life. This narrative review synthesizes emerging pharmacological strategies beyond conventional anticoagulation, with emphasis on the maturity of evidence and on the distinction between thromboprophylaxis, treatment of acute VTE, secondary prevention, and adjunctive thrombus-resolution approaches. Factor XI/activated factor XI (FXI/FXIa) inhibition is the most mature bleeding-sparing platform. In orthopedic thromboprophylaxis, abelacimab, FXI antisense oligonucleotides, milvexian, and osocimab reduced postoperative venous thrombosis with low bleeding signals, but most data still come from prophylaxis rather than treatment trials. By contrast, fibrinolysis-enhancing strategies targeting α2-antiplasmin, plasminogen activator inhibitor-1 (PAI-1), or thrombin-activatable fibrinolysis inhibitor (TAFI) seek to accelerate endogenous clot resolution and possibly reduce long-term disability, yet current clinical evidence remains early phase. Thrombo-inflammatory approaches targeting selectins or P-selectin glycoprotein ligand-1 (PSGL-1) have strong mechanistic rationale but limited direct clinical confirmation. Overall, the VTE pipeline is moving from broad suppression of coagulation toward mechanism-based strategies matched to specific clinical problems: bleeding-sparing anticoagulation, safer clot-resolution adjuncts, and therapies directed at vein wall injury. At present, FXI inhibition appears closest to clinical translation, whereas fibrinolysis-enhancing and thrombo-inflammatory approaches remain exploratory. Wider adoption will depend on phase 3 treatment outcomes, evidence in cancer and organ dysfunction, reversibility, cost-effectiveness, and integration into clinical guidelines.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13474715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148206098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in patients with atrial fibrillation with and without heart failure on oral anticoagulants: a multicenter retrospective cohort study.","authors":"Xiaomin Dong, Shuyi Wu, Xinhai Huang, Yanxian Lan, Cuifang You, Shuzheng Jiang, Jinhua Zhang","doi":"10.1186/s12959-026-00883-4","DOIUrl":"10.1186/s12959-026-00883-4","url":null,"abstract":"<p><strong>Background: </strong>Multicenter real-world data on anticoagulated patients with atrial fibrillation (AF) and heart failure (HF) remain limited, particularly in Chinese populations. This study compared clinical outcomes in AF patients receiving oral anticoagulants (OACs) according to HF status.</p><p><strong>Methods: </strong>We conducted a multicenter retrospective cohort study across four hospitals in China and included 4,878 AF patients who received OACs after discharge between January 2019 and August 2023. Patients were classified into HF (n = 2,371) and non-HF (n = 2,507) groups and followed for a median of 19 months. a. Logistic regression analysis was used to assess the associations between HF and clinical outcomes. Propensity score matching (PSM) was to matched HF and no-HF cohorts and to compare rivaroxaban with warfarin among patients with HF.</p><p><strong>Results: </strong>After multivariable adjustment, HF was independently associated with higher risk of all-cause death(adjusted OR 1.414, 95% CI 1.118-1.787; P = 0.004), and not significantly different in risks of total bleeding, major bleeding, gastrointestinal bleeding, intracranial hemorrhage, minor bleeding, thrombosis, or ischemic stroke compare with non-HF. After 1:1 PSM, HF remained associated with higher risk of all-cause death. In the matched HF subgroup, rivaroxaban was associated with lower risk of all-cause death than warfarin (OR 0.619, 95% CI 0.422-0.907; P = 0.014).</p><p><strong>Conclusion: </strong>Among AF patients receiving OACs, concomitant HF was associated with increased risk of all-cause death. In the matched HF subgroup, rivaroxaban was associated with lower risk of all-cause death than warfarin. These findings should be interpreted cautiously given the retrospective observational design and the lack of INR and time-in-therapeutic-range data for warfarin-treated patients.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13474917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148212209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma PF4 is a reliable biomarker of platelet reactivity and predictive of bleeding risk in DAPT patients undergoing cardiac surgery.","authors":"Joseph Roux de Bezieux, Julien Amour, Aurélien Philippe, Jeanne Rancic, Nicolas Gendron, Sébastien Bertil, Marc Garnier, Pascale Gaussem, David M Smadja","doi":"10.1186/s12959-026-00880-7","DOIUrl":"10.1186/s12959-026-00880-7","url":null,"abstract":"<p><strong>Background: </strong>Platelet activation is crucial for hemostasis and thrombosis, particularly in patients on antiplatelet therapy. Managing bleeding risk during cardiac surgery requires understanding platelet dynamics, especially when antiplatelet agents are maintained until the coronary artery bypass surgery (CABG).</p><p><strong>Aims: </strong>to explore the relevance of plasma levels of sCD40L, sP-Selectin, PF4, and NAP-2 in predicting bleeding events during CABG in patients under dual antiplatelet therapy (clopidogrel+aspirin, DAPT) or aspirin.</p><p><strong>Methods: </strong>Platelet reactivity before CABG was assessed in 143 patients by plasma levels of sCD40L, sP-Selectin, PF4, and NAP-2 as well as platelet aggregation tests and platelet membrane expression of P-Selectin. Postoperative bleeding was monitored at 24 h with the chest tube blood output.</p><p><strong>Results: </strong>Patients receiving DAPT demonstrated markedly reduced plasma levels of PF4 and NAP-2 compared to patients on aspirin alone (PF4: 676 vs. 992 ng/ml, p < 0.001; NAP-2: 167 vs. 281 ng/ml, p < 0.001). PF4 and NAP-2 levels correlated with 10 and 20 µM ADP-induced and collagen-induced platelet aggregation (p = 0.01) but not with arachidonic acid or PAR1ap as agonists. Platelet membrane P-Selectin expression before CABG was significantly correlated with PF4 and NAP-2 levels (r = 0.26, p < 0.001 for PF4, r = 0.23, p = 0.01 for NAP-2), confirming its role in reflecting basal platelet activation. sP-Selectin and sCD40L showed no significant correlation with any clinical outcomes, treatment group or platelet activation test whereas PF4 and NAP-2 were independently correlated with increased 24-hour bleeding volume (PF4: r =-0.19 p = 0.03; NAP-2: r=-0.17 p = 0.04).</p><p><strong>Conclusion: </strong>PF4 is the most platelet-specific biomarker for predicting platelet reactivity and bleeding in patients receiving DAPT until the CABG. Plasma PF4 quantification could provide a simpler alternative to aggregation tests for predicting platelet reactivity, postoperative bleeding and could guide perioperative antiplatelet management.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13235088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-administration of thrombolytics in massive pulmonary embolism with initial therapy failure: a case report.","authors":"Seyed Amir Hoseini, Maede Aghahoseini, Mohammad Javad Aminizadeh, Fatemeh Sadat Hosseini Khajouei, Negar Azami","doi":"10.1186/s12959-026-00879-0","DOIUrl":"10.1186/s12959-026-00879-0","url":null,"abstract":"<p><strong>Background: </strong>Massive pulmonary embolism (PE) is a life-threatening emergency with high mortality. Systemic thrombolysis is the standard reperfusion therapy for patients with hemodynamic instability. However, when initial thrombolysis fails, therapeutic options are limited and evidence supporting subsequent interventions is scarce.</p><p><strong>Case presentation: </strong>We describe a 45-year-old man with hyperlipidemia and depression who presented with dyspnea, hypoxemia, and cardiogenic shock. Echocardiography revealed right ventricular dilatation and dysfunction, consistent with massive PE. Initial therapy with full-dose alteplase (100 mg) and anticoagulation achieved only transient hemodynamic stabilization. The patient remained severely hypoxemic with persistent right ventricle (RV) dysfunction. As catheter-directed therapy and surgical embolectomy were unavailable, repeat systemic thrombolysis was pursued. A second full dose of alteplase (100 mg) was administered on hospital day four. Within 24 h, oxygen saturation improved from 65% to 92% on room air, and echocardiography confirmed substantial recovery of RV size and function. No major bleeding or other complications occurred during hospitalization.</p><p><strong>Conclusion: </strong>Current guidelines do not recommend repeat thrombolysis for massive PE unresponsive to initial fibrinolysis, and available evidence is confined to case reports. This case demonstrates that, in carefully selected patients without contraindications, repeat systemic thrombolysis may represent a feasible and potentially lifesaving rescue option, particularly in resource-limited settings where other reperfusion strategies are not available. Further studies are needed to define safety, patient selection, and long-term outcomes.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"24 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13224636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148144910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neonatal epicutaneo-cava catheter-related thrombosis: a comprehensive overview.","authors":"Xue Jin, Juan Chen","doi":"10.1186/s12959-026-00877-2","DOIUrl":"10.1186/s12959-026-00877-2","url":null,"abstract":"<p><p>Epicutaneo-cava catheters(n-PICC) are widely used in neonates for long-term nutritional support and medication administration, reducing the need for frequent invasive punctures. However, catheter-related thrombosis (CRT) is a serious complication of n-PICC placement. Due to the developmental immaturity of the neonatal coagulation system, neonates are at an increased risk of thrombosis. Currently, there is no standardized protocol for the diagnosis and management of CRT in neonates. This review summarizes the current understanding of risk factors, diagnostic approaches, treatment strategies, and preventive measures for CRT in neonates, aiming to provide clinical guidance.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148144855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}